Business Wire

SAMSUNG-ELECTRONICS

Share
Samsung Introduces 1.2μm 50Mp ISOCELL GN1 with Faster Auto-focusing and Brighter Images

Samsung Electronics Co., Ltd., a world leader in advanced semiconductor technology, today introduced Samsung ISOCELL GN1, a new 50-megapixel (Mp) image sensor with large 1.2μm-sized pixels. The ISOCELL GN1 is Samsung’s first image sensor to offer both Dual Pixel and Tetracell technologies. Thanks to the relatively larger pixel size, the GN1 brings image sensor performance to a new level with a combination of elevated light sensitivity for stellar low-light photos and DSLR-level auto-focus speeds, optimized for more dynamic picture-taking experiences.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200519005376/en/

“With innovative pixel technologies, Samsung has been at the forefront of offering high-performance image sensors that closely cater to increasingly diversifying market needs. The ISOCELL GN1 is part of that commitment to deliver stunning images to consumers in any environment,” said Yongin Park, executive vice president of sensor business at Samsung Electronics. “We will continue to introduce image sensor solutions at the cutting-edge that will lead the next trends in mobile photography.”

Creating desirable images is an indispensable element for today’s smartphone users who are well accustomed to visually grasping and cherishing special moments, wherever they are. To address various imaging preferences of the users, some smartphone makers put more emphasis on extremely detailed images with ultra-high resolutions, while some choose bigger pixels for bright results in low-light environments. The new Samsung ISOCELL GN1 fulfills these multiple needs at once with Dual Pixel and Tetracell technologies.

The GN1 brings best-in-class auto-focusing with 100 million phase detection auto-focus (PDAF) agents. Samsung’s Dual Pixel technology places two photodiodes side-by-side within a single pixel that can receive light from different angles for phase detection. With all of the sensor’s active pixels working as auto-focusing agents, the GN1 can detect and focus onto a desired still or moving object from every corner in an instant, even in low-light conditions. When capturing images, a single pixel output is created by merging the outputs from the two photodiodes within the pixel. Samsung also provides a software algorithm that takes light information from each photodiode to produce image resolutions comparable to 100Mp.

For ultimate low-light photography, the GN1 adopts Tetracell technology, a pixel-merging technique that improves the pixels’ capacity to capture and process more light. By binning four pixel signals into one, Tetracell doubles the image sensor’s pixel size to 2.4μm and quadruples the light sensitivity to take brighter 12.5Mp photographs. With improved light sensitivity combined with a powerful auto-focusing solution, the GN1 is able to focus on an object quickly even in extreme low-light environment to deliver both brighter and sharper results.

In addition to Dual Pixel and Tetracell technologies, the GN1 comes with Smart-ISO that intelligently selects the optimal ISO, real-time HDR that captures the scene in multiple exposures simultaneously, and gyro-based electronic image stabilization (EIS) that takes sharp images and video even when in motion. For premium video quality, the image sensor supports video recording at up to 8K resolution at 30 frames-per-second (fps).

Samsung ISOCELL GN1 started mass production this month.

About Samsung Electronics Co., Ltd.

Samsung inspires the world and shapes the future with transformative ideas and technologies. The company is redefining the worlds of TVs, smartphones, wearable devices, tablets, digital appliances, network systems, and memory, system LSI, foundry and LED solutions. For the latest news, please visit the Samsung Newsroom at http://news.samsung.com .

# # #

* Samsung first announced its ISOCELL technology in 2013, which reduces color crosstalk between pixels by placing a physical barrier, allowing small-sized pixels to achieve higher color fidelity. Based on this technology, Samsung introduced the industry’s first 1.0μm-pixel image sensor in 2015 and a 0.9-pixel sensor in 2017. In June 2018, Samsung introduced an upgraded pixel isolation technology, the ISOCELL Plus.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release

Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem

Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 11:08:00 CET | Press release

Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played

Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 10:44:00 CET | Press release

At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will

Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 10:00:00 CET | Press release

Anthropic’s safety-first AI meets Allianz's dedication to customer centricity, stakeholder trust, and regulatory excellenceThree focus areas of the partnership: workforce empowerment, operations automation through agentic AI, and regulatory compliance Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE.

MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 07:00:00 CET | Press release

MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD) STARFISH-UC Phase 2b trial is designed to confirm MH002’s early efficacy signals and favorable safety observed in Phase 2a studies MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye